In addition, cfDI showed a sensitivity of 81.7% and a specificity of 78.8% in differentiating PC from BPH with PSA ≥ 4 ng/mL (AUC = 0.910) [57]. This evidence concerns the gene KLK3 and benign prostatic hyperplasia.